In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Hold rating on CareDx (CDNA), with a price target of $27. The company’s shares closed on Friday at $26.56, close to its 52-week high of $30.80.
Selvaraju commented:
“As we roll forward the DCF analysis, our estimated market value of the firm has increased slightly to $1,127M from $1,123M, Our price target is derived from the market value of the firm, which includes a discounted cash flow analysis based asset value for pre- and post-transplant tests, using a 15% discount rate and 2%.”
According to TipRanks.com, Selvaraju ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -13.6% and a 27.5% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, EyePoint Pharmaceuticals Inc, and Bausch Health Companies Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for CareDx with a $36.33 average price target.
See today’s analyst top recommended stocks >>
Based on CareDx’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $19.97 million. In comparison, last year the company had a GAAP net loss of $31.67 million.
Based on the recent corporate insider activity of 52 insiders, corporate insider sentiment is neutral on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
CareDx, Inc. operates as a transplant diagnostics company, which offers pre- and post-transplant continuum. It focuses on discovery, development, and commercialization of diagnostic surveillance solutions.
